NCT04155190Phase 2Terminated

A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Study sponsor: Sol-Gel Technologies, Ltd. · SLGL

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2021-04-23Actual
Enrollment · participants50Actual
Source updated2026-07-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of New Surgically Eligible BCCs (nSEBs). After: Measure: Number of Participants With New Surgically Eligible Basal Cell Carcinomas (nSEBs).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview